Watchlist For March 14: ALZM, USAT, STEM

Stanford Management Ltd (OTC:ALZM) acquired Organ Transport Systems from Healthcare of Today in an all-stock transaction. The acquisition of OTS serves as the first of several planned acquisitions by Allezoe Medical Holdings in the field of medical device development, manufacturing and related services. Michael Holder, President, CEO and Director of OTS, and Hyman White, Secretary, Treasurer and Director of OTS, have been appointed to the Board of Directors of ALZM as result of the acquisition. Mr. Holder will serve as the CEO of Allezoe and Mr. White as its Secretary and Treasurer. Stanford Management stock is currently trading at $1.14. The stock is up 10.68 percent from its previous close. Stanford Management stock touched the high of $1.15 and lowest price in today's session is $1.08. The company stock has traded in the range of $0.35 and $1.20 during the past 52 weeks. The company's market cap is $60.00 million. USA Technologies, Inc. ( NASDAQ:USAT ) signed a securities purchase agreement with institutional investors to purchase $10.7 million of common stock in a private placement. The company will sell an aggregate of 5,200,000 shares of its common stock at $2.064 per share and warrants to purchase up to 3,900,000 additional shares in the aggregate of its common stock as per the agreement. The warrants will be exercisable at an exercise price of $2.6058 per share and will have a five-year term commencing on the initial exercisability date. The offering is expected to close on or before March 24, 2011. USA Technologies stock is currently trading at $2.14. The stock is down 17.05 percent from its previous close. USA Technologies shares touched the high of $2.30 and lowest price in today's session is $2.08. The company stock has traded in the range of $0.46 and $2.75 during the past 52 weeks. The company's market cap is $56.19 million. StemCells, Inc. ( NASDAQ:STEM ) reported a wider loss for the fourth quarter, primarily due to an increase in fair value of warrant liability. The company reported fourth quarter net loss of $9.0 million or $0.07 per share, increased than the loss of $5.2 million or $0.05 per share for the year-ago quarter. The revenue for the quarter increased 67 percent to $699,000 from $418,000 last year, resulting from the receipt of a milestone payment from a licensee, as well as higher product sales revenue from the company’s SC Proven line of media and reagents. The loss from operations for the quarter reduced to $7.7 million from $8.0 million last year. For the full year, the company reported a net loss of $25.2 million or $0.20 per share as compared with a net loss of $27.0 million or $0.25 per share for 2009. The revenue increased 44 percent to $1.4 million from $1.0 million reported in 2009. StemCells stock is currently trading at $0.860. The stock is up 6.03 percent from its previous close. StemCells stock touched the high of $0.87 and lowest price in today's session is $0.82. The company stock has traded in the range of $0.75 and $1.27 during the past 52 weeks. The company's market cap is $105.25 million.
Negocioenlinea
tdp2664Penny Stock Live